Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28585644 | 0.82 | GLO1 (0.44) | MAPTGAAGLO1ALDH1A1MEN1 | |
| SCHEMBL22284199 | 0.81 | HPGD (0.44) | MAPTGAAALDH1A1NOS3NOS2 | |
| SCHEMBL4437414 | 0.81 | HPGD (0.44) | MAPTGAAALDH1A1NOS3NOS2 | |
| SCHEMBL20060955 | 0.81 | HPGD (0.44) | MAPTGAAALDH1A1NOS3NOS2 | |
| SCHEMBL1713680 | 0.81 | MAPT (0.44) | MAPTGAAGLO1ALDH1A1NOS3 | |
| SCHEMBL21644269 | 0.81 | MAPT (0.44) | MAPTGAAGLO1ALDH1A1NOS3 | |
| SCHEMBL632279 | 0.79 | GLO1 (0.41) | MAPTGAAGLO1ALDH1A1KMT2A | |
| SCHEMBL25563386 | 0.79 | GLO1 (0.41) | MAPTGAAGLO1ALDH1A1MEN1 | |
| SCHEMBL11488798 | 0.79 | ALDH1A1 (0.36) | MAPTGAAGLO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11496676 | 0.79 | ALDH1A1 (0.36) | MAPTGAAGLO1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | MAPT 1060/4885GAA 1262/4885GLO1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.